A Phase 1/2, Open-Label, First-In-Human Trial Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Antitumour Activity Of Odm-216 In Participants With Advanced Solid Tumours (BICIDES)

Principal Investigator

Dr Eileen Parkes

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1014309